Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRV006
MIFTS: 56

Pervasive Developmental Disorder

Categories: Mental diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pervasive Developmental Disorder

About this section

MalaCards integrated aliases for Pervasive Developmental Disorder:

Name: Pervasive Developmental Disorder 12 56 15
Pervasive Development Disorder 12 74
Pervasive Developmental Disorders 55
Autism Spectrum Disorders 74
Autistic Behavior 74

Classifications:

MalaCards categories:
Anatomical: Mental diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:0060040
ICD9CM 36 299.80
ICD10 34 F84
Sources

Summaries for Pervasive Developmental Disorder

About this section
NINDS : 55 The diagnostic category of pervasive developmental disorders (PDD) refers to a group of disorders characterized by delays in the development of socialization and communication skills. Parents may note symptoms as early as infancy, although the typical age of onset is before 3 years of age. Symptoms may include problems with using and understanding language; difficulty relating to people, objects, and events; unusual play with toys and other objects; difficulty with changes in routine or familiar surroundings, and repetitive body movements or behavior patterns. Autism (a developmental brain disorder characterized by impaired social interaction and communication skills, and a limited range of activities and interests) is the most characteristic and best studied PDD. Other types of PDD include Asperger's Syndrome, Childhood Disintegrative Disorder, and Rett's Syndrome. Children with PDD vary widely in abilities, intelligence, and behaviors. Some children do not speak at all, others speak in limited phrases or conversations, and some have relatively normal language development. Repetitive play skills and limited social skills are generally evident. Unusual responses to sensory information, such as loud noises and lights, are also common.

MalaCards based summary : Pervasive Developmental Disorder, also known as pervasive development disorder, is related to autism spectrum disorder and asperger syndrome, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Pervasive Developmental Disorder is PPP2R1A (Protein Phosphatase 2 Scaffold Subunit Aalpha), and among its related pathways/superpathways are Neuroscience and Transmission across Chemical Synapses. The drugs Oxytocin and Acetylcholine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A developmental disorder of mental health that refers to a group of five disorders characterized by impairments in socialization and communication, as well as restricted interests and repetitive behaviors.

Wikipedia : 77 The diagnostic category pervasive developmental disorders (PDD), as opposed to specific developmental... more...

Sources

Related Diseases for Pervasive Developmental Disorder

About this section

Diseases related to Pervasive Developmental Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Related Disease Score Top Affiliating Genes
1 autism spectrum disorder 33.2 CHD8 CNTNAP2 FOXP2 GABRB3 MECP2 NLGN3
2 asperger syndrome 32.7 GABRB3 MECP2 NLGN3 NLGN4X SLC6A4
3 autism 32.4 CHD8 CNTNAP2 CTNND2 EIF4E FOXP2 GABRB3
4 specific developmental disorder 32.0 FOXP2 MECP2 SLC6A4
5 attention deficit-hyperactivity disorder 31.3 CNTNAP2 MECP2 NLGN4X SLC6A4 SLC9A9
6 fragile x syndrome 30.6 EIF4E MECP2 SLC6A4
7 childhood disintegrative disease 11.4
8 landau-kleffner syndrome 11.4
9 autism x-linked 1 11.3
10 autism x-linked 2 11.3
11 autism x-linked 3 11.3
12 autism x-linked 4 11.3
13 autism x-linked 5 11.3
14 autism x-linked 6 11.3
15 autism 15 11.3
16 autism 16 11.3
17 autism 17 11.3
18 autism 18 11.3
19 autism 8 11.2
20 autism 3 11.2
21 autism 6 11.2
22 autism 7 11.2
23 autism 11 11.2
24 autism 12 11.2
25 potocki-lupski syndrome 11.2
26 autism 13 11.2
27 autism 9 11.2
28 autism 10 11.2
29 chromosome 16p11.2 deletion syndrome, 220-kb 11.0
30 autism 19 11.0
31 mental retardation, autosomal recessive 41 11.0
32 rett syndrome 11.0
33 atypical autism 11.0
34 pol iii-related leukodystrophies 10.6
35 epilepsy 10.5
36 x-linked non-specific intellectual disability 10.4 MECP2 NLGN4X PTCHD1
37 mental retardation, autosomal dominant 26 10.3
38 anxiety 10.3
39 speech and communication disorders 10.3 CNTNAP2 FOXP2 MECP2
40 schizophrenia 10.3
41 bipolar disorder 10.3
42 gilles de la tourette syndrome 10.2
43 alacrima, achalasia, and mental retardation syndrome 10.2
44 colitis 10.2
45 articulation disorder 10.2 CNTNAP2 FOXP2
46 hyperlexia 10.1
47 angelman syndrome 10.0
48 obsessive-compulsive disorder 10.0
49 prader-willi syndrome 10.0
50 cognitive function 1, social 10.0

Graphical network of the top 20 diseases related to Pervasive Developmental Disorder:



Diseases related to Pervasive Developmental Disorder
Sources

Symptoms & Phenotypes for Pervasive Developmental Disorder

About this section

UMLS symptoms related to Pervasive Developmental Disorder:


photophobia, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances

GenomeRNAi Phenotypes related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.89 MEFV
2 Decreased viability GR00381-A-1 9.89 CHD8 EIF4E KCND2 MEFV RPL10 SCT
3 Decreased viability GR00381-A-3 9.89 SLC6A4
4 Decreased viability GR00402-S-2 9.89 EIF4E KCND2 MEFV RPL10 SCT SLC6A4
5 Decreased viability after Maraba virus infection GR00252-A-1 9.74 CHD8 FOXP2 GABRB3 PTCHD1 SCT SHANK2
6 Decreased viability after Maraba virus infection GR00252-A-2 9.74 CHD8 FOXP2 GABRB3 PTCHD1 SCT SHANK2
7 Decreased viability after Maraba virus infection GR00252-A-3 9.74 FOXP2

MGI Mouse Phenotypes related to Pervasive Developmental Disorder:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 CHD8 CNTNAP2 CTNND2 GABRB3 KCND2 MECP2
2 growth/size/body region MP:0005378 9.73 CHD8 CNTNAP2 GABRB3 MECP2 MEFV NLGN3
3 nervous system MP:0003631 9.4 CHD8 CNTNAP2 CTNND2 GABRB3 KCND2 MECP2
Sources

Drugs & Therapeutics for Pervasive Developmental Disorder

About this section

Drugs for Pervasive Developmental Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 406)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-56-6 439302 53477758
2
Acetylcholine Approved, Investigational Phase 4,Phase 1,Not Applicable 51-84-3 187
3
Donepezil Approved Phase 4,Phase 2,Phase 1 120014-06-4 3152
4
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
5
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
6
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 113-45-1 4158
7
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 19982-08-2 4054
8
Guanfacine Approved, Investigational Phase 4,Not Applicable 29110-47-2 3519
9
Buspirone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 36505-84-7 2477
10
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Not Applicable 616-91-1 12035
11
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
12
Norepinephrine Approved Phase 4,Not Applicable 51-41-2 439260
13
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
14
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
15
Olanzapine Approved, Investigational Phase 4,Phase 2,Phase 3 132539-06-1 4585
16
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106266-06-2 5073
17
Minocycline Approved, Investigational Phase 4,Phase 1 10118-90-8 5281021
18
Valproic Acid Approved, Investigational Phase 4,Phase 2 99-66-1 3121
19
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
20
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
21
Choline Approved, Nutraceutical Phase 4 62-49-7 305
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59-30-3 6037
23
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 73-31-4 896
24
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
25 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Oxytocics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Lipid Regulating Agents Phase 4,Not Applicable
28 Vasodilator Agents Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable
29 Nootropic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Hypolipidemic Agents Phase 4,Not Applicable
34 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
36 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Dopamine D2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
40 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
41 Dopamine agonists Phase 4,Phase 3,Phase 2
42 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Serotonin Receptor Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Serotonin 5-HT2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
47 Serotonin 5-HT1 Receptor Agonists Phase 4,Phase 3,Phase 2
48 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Rho(D) Immune Globulin Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 934)
# Name Status NCT ID Phase Drugs
1 Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders Unknown status NCT02940574 Phase 4 Syntocinon (Oxytocin)
2 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders Unknown status NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
3 Study to Evaluate the Efficacy and Safety of Aripiprazole Unknown status NCT02069977 Phase 4 Aripiprazole
4 An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum Unknown status NCT02199925 Phase 4 Gammaplex 5%
5 A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders Completed NCT01333865 Phase 4 Memantine
6 FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders Completed NCT01028820 Phase 4 Aripiprazole
7 Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder Completed NCT01238575 Phase 4 extended-release guanfacine
8 Improving Driving in Young People With Autism Spectrum Disorders Recruiting NCT03538431 Phase 4 Buspirone
9 Omega-3 Fatty Acids in Autism Spectrum Disorders Completed NCT01695200 Phase 4
10 Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD) Using Telepsychiatry of Complementary and Alternative Treatments Not yet recruiting NCT03757585 Phase 4 Open-label Treatment with Omega-3 Fatty Acids + Inositol;Open-label Treatment with N-Acetyl Cysteine
11 Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders Terminated NCT01033565 Phase 4 Natrol
12 Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD Completed NCT02096952 Phase 4 Methylphenidate extended-release liquid formulation
13 Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder Completed NCT00380692 Phase 4 Atomoxetine;Placebo
14 Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism Recruiting NCT03337646 Phase 4 Lisdexamfetamine Dimesylate
15 Atomoxetine, Placebo and Parent Management Training in Autism Completed NCT00844753 Phase 4 atomoxetine;Placebo
16 Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes Enrolling by invitation NCT03333629 Phase 4
17 Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study Completed NCT02255565 Phase 4 Very Low Dose Quillivant XR;Low Dose Quillivant XR;Moderate Dose Quillivant XR
18 Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood Completed NCT01683565 Phase 4 LCPUFA oil supplement
19 Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism Completed NCT01337700 Phase 4 Milnacipran;Placebo
20 Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism Completed NCT02235467 Phase 4
21 A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD Completed NCT00485849 Phase 4 Atomoxetine Hydrochloride
22 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Completed NCT01339858 Phase 4 N-Acetyl Cysteine
23 An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications. Completed NCT00391261 Phase 4 Metformin
24 Metabolic Effects of Antipsychotics in Children Completed NCT00205699 Phase 4 risperidone;olanzapine;aripiprazole
25 Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART) Completed NCT01333072 Phase 4 Aripiprazole;Risperidone
26 Minocycline to Treat Childhood Regressive Autism Completed NCT00409747 Phase 4 Minocycline
27 Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study Completed NCT00352196 Phase 4 Risperidone
28 Divalproex Sodium ER in Adult Autism Completed NCT00211796 Phase 4 Divalproex Sodium ER
29 Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder Completed NCT01227668 Phase 4 Aripiprazole;Placebo
30 A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder Completed NCT00576732 Phase 4 Placebo;Risperidone high dose;Risperidone low dose
31 A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and Apnea in Infants Active, not recruiting NCT00756600 Phase 4 Regional Anesthesia;General Anesthesia
32 A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children Completed NCT01050582 Phase 4 Risperidone;Other atypical antipsychotic drugs
33 Group Psychoeducational Program for Mothers of Children With High Functional Pervasive Developmental Disorders Unknown status NCT01243905 Phase 2, Phase 3
34 Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders Unknown status NCT02757066 Phase 2, Phase 3 NPC-15 Granules Lower Dose;NPC-15 Granules Higher Dose;NPC-15 Placebo Granule
35 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
36 Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders Completed NCT00870727 Phase 3 Aripiprazole oral product;Placebo oral capsule
37 Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders Completed NCT01302964 Phase 3 Placebo;Mirtazapine
38 Oxytocin in Adolescents With Autism Spectrum Disorders Suspended NCT02007447 Phase 2, Phase 3 OCYTOCINA - SPRAY NASAL
39 D-Cycloserine and Social Skills Training in Autism Spectrum Disorders Completed NCT01086475 Phase 3 D-cycloserine;Placebo
40 Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder Completed NCT01972074 Phase 3 Memantine;Placebo
41 Cortical Metrics in Intervention Trials With Autism Spectrum Disorders Withdrawn NCT02212275 Phase 2, Phase 3 Dextromethophan
42 A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder Active, not recruiting NCT02985749 Phase 3 Intranasal Oxytocin
43 A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension Recruiting NCT03504917 Phase 3 Balovaptan;Placebo
44 Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders Completed NCT02081027 Phase 2, Phase 3 Riluzole;placebo
45 Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder. Recruiting NCT03715153 Phase 3 BUMETANIDE/S95008;PLACEBO
46 Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders Terminated NCT01706523 Phase 3 STX209 (arbaclofen)
47 A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD) Completed NCT00261508 Phase 3 risperidone
48 Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD) Completed NCT01825798 Phase 3 Metformin;Placebo
49 Psychotherapy for Anxiety in Children With Autism Spectrum Disorder Completed NCT02028247 Phase 3
50 Encopresis & MIE (DoD #2) Recruiting NCT03197922 Phase 3

Search NIH Clinical Center for Pervasive Developmental Disorder

Sources

Genetic Tests for Pervasive Developmental Disorder

About this section
Sources

Anatomical Context for Pervasive Developmental Disorder

About this section

MalaCards organs/tissues related to Pervasive Developmental Disorder:

42
Brain, Testes, Eye, Bone, Heart, Liver, Bone Marrow
Sources

Publications for Pervasive Developmental Disorder

About this section

Articles related to Pervasive Developmental Disorder:

(show top 50) (show all 251)
# Title Authors Year
1
Neonatal factors among subjects diagnosed with a pervasive developmental disorder in the US. ( 28462601 )
2017
2
Autism Spectrum/Pervasive Developmental Disorder. ( 27262008 )
2016
3
Are There Differences in Neurocognition and Social Cognition Among Adolescents with Schizophrenia, a Pervasive Developmental Disorder, and Both Disorders? ( 27015370 )
2016
4
Hemispheric Processing of Idioms and Irony in Adults With and Without Pervasive Developmental Disorder. ( 26070277 )
2015
5
A Prospective Longitudinal Assessment of Medical Records for Diagnostic Substitution among Subjects Diagnosed with a Pervasive Developmental Disorder in the United States. ( 26528457 )
2015
6
The Stability of Comorbid Psychiatric Disorders: A 7A Year Follow Up of Children with Pervasive Developmental Disorder-Not Otherwise Specified. ( 26456972 )
2015
7
Examining the criterion-related validity of the Pervasive Developmental Disorder Behavior Inventory. ( 24463433 )
2014
8
Effect of levetiracetam on behavioral problems in pervasive developmental disorder children with epilepsy. ( 24703761 )
2014
9
Psychiatric comorbidity in children with high-functioning pervasive developmental disorder. ( 25272562 )
2014
10
Detecting Subgroups in Children Diagnosed with Pervasive Developmental Disorder - Not Otherwise Specified. ( 25374133 )
2014
11
A comparison of DSM-IV pervasive developmental disorder and DSM-5 autism spectrum disorder prevalence in an epidemiologic sample. ( 24745950 )
2014
12
Sunsetting DSM-IV's pervasive developmental disorder. ( 24745948 )
2014
13
Psychological interventions in pervasive developmental disorder: An overview. ( 25788797 )
2014
14
Sensory hypersensitivity in children with high-functioning pervasive developmental disorder. ( 25803881 )
2014
15
A Case-Control Study Evaluating the Relationship Between Thimerosal-Containing Haemophilus influenzae Type b Vaccine Administration and the Risk for a Pervasive Developmental Disorder Diagnosis in the United States. ( 25382662 )
2014
16
Catatonic features in adolescents with schizophrenia with and without a comorbid pervasive developmental disorder. ( 24914405 )
2014
17
Diagnostic Boundaries of Autism Disorder Vs Pervasive Developmental Disorder Nos: Comparative Observational Study and Literature Review. ( 24050746 )
2013
18
Brief report: An unusual manifestation of diagnostic overshadowing of pervasive developmental disorder--not otherwise specified: a five year longitudinal case study. ( 23108987 )
2013
19
Comparison of pervasive developmental disorder and schizophrenia by the Japanese version of the National Adult Reading Test. ( 22335467 )
2013
20
Psychiatric diagnostic screening of social maladaptive behaviour in children with mild intellectual disability: differentiating disordered attachment and pervasive developmental disorder behaviour. ( 23906477 )
2013
21
Reduced brain activation during imitation and observation of others in children with pervasive developmental disorder: a pilot study. ( 23718943 )
2013
22
Dual copy number variants involving 16p11 and 6q22 in a case of childhood apraxia of speech and pervasive developmental disorder. ( 22909776 )
2013
23
Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. ( 24130822 )
2013
24
Pervasive developmental disorder in the children of immigrant parents: comparison of different assessment instruments. ( 24394875 )
2013
25
Anxiety in children with high-functioning pervasive developmental disorder. ( 23909078 )
2013
26
Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study. ( 23782127 )
2013
27
Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study. ( 23194148 )
2012
28
Sexual obsessions, compulsions, suicidality and homicidality in an adolescent diagnosed with bipolar disorder not otherwise specified, obsessive-compulsive disorder, pervasive developmental disorder not otherwise specified, and mild mental retardation. ( 22612525 )
2012
29
Executive function in children with pervasive developmental disorder and attention-deficit/hyperactivity disorder assessed by the Keio version of the Wisconsin card sorting test. ( 21917389 )
2012
30
A case of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) coexisting with pervasive developmental disorder harboring SCN1A mutation in addition to CHRNB2 mutation. ( 23032131 )
2012
31
Is recovery from a pervasive developmental disorder possible? ( 22353321 )
2012
32
Is long-term prognosis for pervasive developmental disorder not otherwise specified different from prognosis for autistic disorder? Findings from a 30-year follow-up study. ( 21713590 )
2012
33
Using virtual reality environment to improve joint attention associated with pervasive developmental disorder. ( 22776822 )
2012
34
Novel AGTR2 missense mutation in a Japanese boy with severe mental retardation, pervasive developmental disorder, and epilepsy. ( 22269148 )
2012
35
Focal EEG abnormalities might reflect neuropathological characteristics of pervasive developmental disorder and attention-deficit/hyperactivity disorder. ( 22225922 )
2012
36
Multi-channel near-infrared spectroscopy shows reduced activation in the prefrontal cortex during facial expression processing in pervasive developmental disorder. ( 22250607 )
2012
37
Brief report: prevalence of pervasive developmental disorder in Brazil: a pilot study. ( 21337063 )
2011
38
Possible evidence for a fall in the prevalence of high-functioning pervasive developmental disorder with age? ( 22937245 )
2011
39
Toward specifying pervasive developmental disorder-not otherwise specified. ( 21298812 )
2011
40
New onset of psychotic symptoms in an adolescent with pervasive developmental disorder, not otherwise specified. ( 21309699 )
2011
41
Analysis of Copper and Zinc Plasma Concentration and the Efficacy of Zinc Therapy in Individuals with Asperger's Syndrome, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) and Autism. ( 22174567 )
2011
42
The specific impairment of fearful expression recognition and its atypical development in pervasive developmental disorder. ( 21919566 )
2011
43
Liquid melatonin via gastrostomy as an alternative hypnotic in a child with pervasive developmental disorder. ( 21663434 )
2011
44
Evaluation of oxidative stress status in children with pervasive developmental disorder and attention deficit hyperactivity disorder using urinary-specific biomarkers. ( 21605498 )
2011
45
Retrospective case report: evaluation of pain in a child with pervasive developmental disorder. ( 21552087 )
2011
46
Buspirone for bruxism in a child with pervasive developmental disorder-not otherwise specified. ( 22136097 )
2011
47
Epilepsy in pervasive developmental disorder without brain MRI abnormalities. ( 20863637 )
2011
48
Abnormal brain protein synthesis in language areas of children with pervasive developmental disorder: a L-[1-11C]-leucine PET study. ( 21636781 )
2011
49
Is pervasive developmental disorder not otherwise specified less stable than autistic disorder? A meta-analysis. ( 21153874 )
2011
50
Effectiveness of modified parent training for mothers of children with Pervasive Developmental Disorder on parental confidence and children's behavior. ( 20385459 )
2011
Sources

Variations for Pervasive Developmental Disorder

About this section

ClinVar genetic disease variations for Pervasive Developmental Disorder:

6 (show top 50) (show all 94)
# Gene Variation Type Significance SNP ID Assembly Location
1 ASF1A; CEP85L; DCBLD1; FAM184A; GOPC; MCM9; NUS1; PLN; SLC35F1 NC_000006.11 deletion Pathogenic GRCh37 Chromosome 6, 117810940: 119417749
2 WFS1 NM_006005.3(WFS1): c.2603G> A (p.Arg868His) single nucleotide variant Conflicting interpretations of pathogenicity rs56393026 GRCh38 Chromosome 4, 6302398: 6302398
3 WFS1 NM_006005.3(WFS1): c.2603G> A (p.Arg868His) single nucleotide variant Conflicting interpretations of pathogenicity rs56393026 GRCh37 Chromosome 4, 6304125: 6304125
4 PPP2R1A NM_014225.5(PPP2R1A): c.773G> A (p.Arg258His) single nucleotide variant Pathogenic rs863225094 GRCh37 Chromosome 19, 52716329: 52716329
5 PPP2R1A NM_014225.5(PPP2R1A): c.773G> A (p.Arg258His) single nucleotide variant Pathogenic rs863225094 GRCh38 Chromosome 19, 52213076: 52213076
6 MEFV NM_000243.2(MEFV): c.2080A> G (p.Met694Val) single nucleotide variant Pathogenic/Likely pathogenic rs61752717 GRCh37 Chromosome 16, 3293407: 3293407
7 MEFV NM_000243.2(MEFV): c.2080A> G (p.Met694Val) single nucleotide variant Pathogenic/Likely pathogenic rs61752717 GRCh38 Chromosome 16, 3243407: 3243407
8 TBR1 NM_006593.4(TBR1): c.1588_1594dup (p.Thr532Argfs) duplication Likely pathogenic rs869312704 GRCh37 Chromosome 2, 162280277: 162280283
9 TBR1 NM_006593.4(TBR1): c.1588_1594dup (p.Thr532Argfs) duplication Likely pathogenic rs869312704 GRCh38 Chromosome 2, 161423766: 161423772
10 RSRC2 NM_023012.5(RSRC2): c.425G> A (p.Arg142Gln) single nucleotide variant Likely pathogenic rs752134549 GRCh37 Chromosome 12, 123001951: 123001951
11 RSRC2 NM_023012.5(RSRC2): c.425G> A (p.Arg142Gln) single nucleotide variant Likely pathogenic rs752134549 GRCh38 Chromosome 12, 122517404: 122517404
12 46;XY;inv(3)(p13q21)dn inversion Pathogenic
13 46;XY;t(6;9)(q16.2;q13)dn Translocation Uncertain significance
14 46;XY;t(3;6)(q26.2;q16.2)dn Translocation Uncertain significance
15 46;XY;t(2;9)(p13;q34.3)pat Translocation Uncertain significance
16 46;XX;inv(3)(q13.2q28-29)dn inversion Uncertain significance
17 46;XY;t(7;19)(q32;q13.1)dn Translocation Pathogenic
18 46;XX;t(5;10)(p13.3;q21.1)dn Translocation Uncertain significance
19 46;XY;t(6;12)(q14;q24);20p+dn complex Pathogenic
20 46;XY;t(2;22)(q23;q13)dn Translocation Pathogenic
21 46;XY;t(9;11)(q34;p11.2)dn Translocation Pathogenic
22 46;XY;t(8;10)(q13;p13)dn Translocation Pathogenic
23 46;XX;t(6;13)(q21;q32)dn Translocation Likely pathogenic
24 46;XY;t(1;2)(q31.2;p15) Translocation Likely pathogenic
25 46;XX;inv(7)(q11.23q36.3)dn inversion Pathogenic
26 46;XY;t(3;5)(q23;q13)dn Translocation Likely pathogenic
27 46;XY;t(2;6)(q33;q21)dn Translocation Pathogenic
28 46;XX;inv(5)(p12q13.1)dn inversion Likely pathogenic
29 46;XY;t(1;4)(q21.3;p15.2)dn Translocation Likely pathogenic
30 46;XY;t(1;12)(p32;p13)dn Translocation Likely pathogenic
31 46;XY;t(4;7)(q31;q22)dn Translocation Uncertain significance
32 46;XX;t(12;17)(q13.1;q11.2)dn Translocation Uncertain significance
33 46;XY;t(5;15)(q11.2;q24) Translocation Pathogenic
34 46;XY;inv(2)(q11.2q24.2)dn inversion Uncertain significance
35 46;XX;t(9;16)(q22.3;p11.2)dn Translocation Uncertain significance
36 46;XY;inv(12)(p12.1q21.2)dn inversion Pathogenic
37 46;XX;t(3;14)(q25;q11.2)dn Translocation Pathogenic
38 46;XY;t(13;14)(q32;q21.2) Translocation Uncertain significance
39 46;XY;t(2;18)(p16.2;q21.1) Translocation Uncertain significance
40 46;XX;inv(5)(q14q33)dn inversion Uncertain significance
41 46;XX;t(X;19)(p11.4;q13.3) Translocation Uncertain significance
42 46;XY;t(1;4)(q32;q11) Translocation Uncertain significance
43 46;XX;t(6;21)(q14;q21)dn Translocation Likely pathogenic
44 46;XY;t(2;10)(p15;p14)dn Translocation Uncertain significance
45 46;XX;t(19;21)(q13.3;q22.3)dn Translocation Pathogenic
46 46;XY;t(3;18)(q13.31;q22.1)dn Translocation Pathogenic
47 46;XY;t(1;3)(p32.1;p25) Translocation Uncertain significance
48 FMR1 NM_002024.5(FMR1): c.199-2A> G single nucleotide variant Likely pathogenic rs1057518850 GRCh37 Chromosome X, 147009838: 147009838
49 FMR1 NM_002024.5(FMR1): c.199-2A> G single nucleotide variant Likely pathogenic rs1057518850 GRCh38 Chromosome X, 147928320: 147928320
50 WFS1 NM_001145853.1(WFS1): c.2540G> A (p.Cys847Tyr) single nucleotide variant Uncertain significance rs1394576939 GRCh38 Chromosome 4, 6302335: 6302335
Sources

Expression for Pervasive Developmental Disorder

About this section
Search GEO for disease gene expression data for Pervasive Developmental Disorder.
Sources

Pathways for Pervasive Developmental Disorder

About this section

Pathways related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
11.99 CNTNAP2 KCND2 MECP2 SHANK2
2
Transmission across Chemical Synapses 67
Show member pathways
 11.95 GABRB3 KCND2 NLGN3 NLGN4X SHANK2 SLC6A4
3
Cell adhesion molecules (CAMs) 38
11.66 CNTNAP2 NLGN3 NLGN4X
4
Protein-protein interactions at synapses 67
Show member pathways
 11.55 NLGN3 NLGN4X SHANK2
5
Serotonergic synapse 38
11.19 GABRB3 KCND2 SLC6A4
Sources

GO Terms for Pervasive Developmental Disorder

About this section

Cellular components related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cell projection GO:0042995 9.91 CNTNAP2 CTNND2 KCND2 MEFV PPP2R1A SHANK2
2 synapse GO:0045202 9.85 GABRB3 KCND2 NLGN3 NLGN4X SHANK2
3 postsynaptic density GO:0014069 9.71 CTNND2 KCND2 NLGN4X SHANK2
4 perikaryon GO:0043204 9.69 CNTNAP2 CTNND2 KCND2
5 presynapse GO:0098793 9.67 NLGN3 NLGN4X SLC6A4
6 postsynaptic membrane GO:0045211 9.67 GABRB3 KCND2 NLGN4X SHANK2
7 cell junction GO:0030054 9.5 CNTNAP2 CTNND2 GABRB3 KCND2 NLGN3 NLGN4X
8 postsynapse GO:0098794 9.48 MECP2 NLGN3
9 spanning component of membrane GO:0089717 9.32 NLGN3 NLGN4X
10 asymmetric, glutamatergic, excitatory synapse GO:0098985 9.26 NLGN3 NLGN4X
11 symmetric, GABA-ergic, inhibitory synapse GO:0098983 9.16 NLGN3 NLGN4X
12 dendrite GO:0030425 9.1 CNTNAP2 CTNND2 KCND2 NLGN4X PPP2R1A SHANK2

Biological processes related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 brain development GO:0007420 9.72 CHD8 CNTNAP2 MECP2 SCT SLC6A4
2 memory GO:0007613 9.71 MECP2 SHANK2 SLC6A4
3 synapse assembly GO:0007416 9.65 MECP2 NLGN3 SHANK2
4 positive regulation of excitatory postsynaptic potential GO:2000463 9.62 NLGN3 SHANK2
5 positive regulation of mesenchymal cell proliferation GO:0002053 9.62 FOXP2 TBX1
6 regulation of AMPA receptor activity GO:2000311 9.61 NLGN3 SHANK2
7 brain morphogenesis GO:0048854 9.61 SHANK2 SLC6A4
8 cerebellum development GO:0021549 9.61 FOXP2 MECP2 NLGN4X
9 dendritic spine morphogenesis GO:0060997 9.6 CTNND2 SHANK2
10 startle response GO:0001964 9.59 CHD8 MECP2
11 neuron cell-cell adhesion GO:0007158 9.58 NLGN3 NLGN4X
12 presynapse assembly GO:0099054 9.58 NLGN3 NLGN4X
13 long-term synaptic potentiation GO:0060291 9.58 MECP2 NLGN3 SHANK2
14 regulation of respiratory gaseous exchange by neurological system process GO:0002087 9.57 MECP2 NLGN3
15 thalamus development GO:0021794 9.56 CNTNAP2 PTCHD1
16 adult behavior GO:0030534 9.56 CNTNAP2 NLGN3 NLGN4X SHANK2
17 presynaptic membrane assembly GO:0097105 9.55 NLGN3 NLGN4X
18 learning GO:0007612 9.55 CNTNAP2 MECP2 NLGN3 NLGN4X SHANK2
19 synapse organization GO:0050808 9.54 CTNND2 NLGN3 NLGN4X
20 inhibitory postsynaptic potential GO:0060080 9.52 GABRB3 NLGN3
21 negative regulation of excitatory postsynaptic potential GO:0090394 9.51 NLGN3 NLGN4X
22 postsynaptic membrane assembly GO:0097104 9.49 NLGN3 NLGN4X
23 vocal learning GO:0042297 9.46 CNTNAP2 FOXP2
24 social behavior GO:0035176 9.28 CHD8 CNTNAP2 MECP2 NLGN3 NLGN4X PTCHD1
25 vocalization behavior GO:0071625 9.26 CNTNAP2 NLGN3 NLGN4X SHANK2

Molecular functions related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.86 CHD8 CNTNAP2 CTNND2 EIF4E FOXP2 KCND2
2 translation regulator activity GO:0045182 8.85 RPL10
3 neurexin family protein binding GO:0042043 8.62 NLGN3 NLGN4X
Sources

Sources for Pervasive Developmental Disorder

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....